We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmacopeia has announced the initiation of a Phase I clinical study of PS433540, a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy.
BioLineRx has successfully completed Phase I clinical trials of BL-1020, the first antipsychotic enhanced with gamma-aminobutyric acid (GABA) for the treatment of schizophrenia.
Ark Therapeutics announced it has held scientific advice meetings with the FDA and the European Medicines Evaluation Agency regarding its planned Phase III trial of Vitor, an oral therapy in development for treating the weight loss and muscle wasting (cachexia) associated with cancer.
Schwarz Pharma announced that a Phase III trial of lacosamide for the treatment of diabetic neuropathy showed statistically significant superiority versus placebo in the primary endpoint.
OrthoLogic has announced findings of a post hoc subgroup analysis of data from its Phase III clinical trial of the novel synthetic peptide Chrysalin (TP508) in unstable, displaced distal radius (wrist) fractures.
Merck announced that the FDA has accepted for standard review two supplemental new drug applications (sNDAs) for Januvia, and the company expects FDA action on both sNDAs by mid-October.
Roche has filed an application with regulatory authorities in Europe requesting an extension of the current Tamiflu license to include smaller capsules of 30 and 45 mg in addition to the 75-mg capsule already registered.
Peregrine Pharmaceuticals has reported preliminary top-line results from a Phase Ib study of its targeted immunotherapy bavituximab in patients with chronic hepatitis C virus (HCV) infection.
Aida Pharmaceuticals announced that its subsidiary, Shanghai Qiaer Biotechnology, has formally begun the large-scale Phase II trials of Rh-Apo2L throughout mainland China.